HSKA Stock Makes Record-Breaking Volume Growth: Is It a Buy Signal? Technical analysis reveals a remarkable 341% increase in volume compared to the 65-Day Volume Moving Average, accompanied by a bullish signal from the Aroon Indicator. Find out the potential implications for investors in our latest article.
Laboratory Corporation of America Holdings posted fourth-quarter 2022 adjusted earnings per share of $4.14, topping analysts' estimates of $4.10. The figure was also down -38.8% from the year-ago quarter’s figure. Revenues were down -9.4% year-over-year to $3.67 billion, missing the Street estimates of $3.74 billion (according to Refinitiv data). Organic revenues fell -9.4%, amid a -13.4%...
Cathie Wood, chief executive of Ark Investment Management, unloaded 175,491 shares of Exact Sciences on Jan. 23, possibly to take advantage of the stock’s recent gains. Exact Sciences is the largest holding in Wood’s flagship Ark Innovation ETF. Exact Sciences, a medical diagnostics company, has lost 11% in its stock price over the past year, but has climbed +119% since Oct. 14 on the back of...
Centogene incurred a net loss of -€11.9m for the second quarter, which was wider by -48% compared to 2Q 2021. On a per-share basis, loss was -€0.44 (vs. - €0.37 loss in the year-ago quarter). Revenue plunged -78% year-over-year to €11.2m in the quarter, missing analysts’ estimates by 3.1%...
Shares of SmileDirectClub dropped on Tuesday, followed by second quarter results that came in lower than expected by analysts.
The teledentistry company’s second-quarter net loss of -14 cents a share was wider than the -12 cents a share anticipated by analysts surveyed by FactSet.FactSet's poll reveals analysts’ expectation of $783.4 million.
Enzo Biochem posted a strong increase in revenue for its fiscal 2021 second quarter, ended Jan. 31, amid strong demand for the life sciences’ company’s testing equipment amid COVID-19 pandemic. Revenue climbed +62% year-over-year to $31.5 million in the quarter. The company’s earnings came in at 5 cents a share, compared to a year-ago loss of - 16 cents a share. “Our open system approach...
On Wednesday, drug and medical device maker ICON said it agreed to buy PRA Health Sciences in a deal valued at approximately $12 billion. Under terms of the deal, ICON will pay PRA Health Sciences shareholders $80 in cash and 0.4125 a share of Icon stock—which represents around 30% premium to PRA’s closing price Tuesday. After the acquisition happens, ICON shareholders will own 66% of the...
Molecular diagnostics company Exact Sciences has agreed to buy cancer-detection company Thrive Earlier Detection for $2.5 billion in cash and stock.
Under the terms of the 65% stock-35% cash deal, Thrive Earlier Detection will receive $1.7 billion up front .An additional $450 million will be payable to Thrive subject to milestones related to the development and commercialization of a blood-based, multi-cancer screening test.
Exact Sciences CEO Kevin Conroy said that the acquisition will allow Exact Sciences to add Thrive's early-stage cancer-screening test, CancerSEEK, into its blood-based screening platform.
Medical equipment provider Thermo Fisher Scientific (NYSE: TMO) has been trending higher for over two and a half years.One of the biggest reasons behind the rally has been good, consistent fundamentals.
Over the last three years the company has been able to grow earnings at a rate of 15% per year while sales have grown at a rate of 14% per year.
Waters Corporation reported fourth-quarter 2018 non-GAAP earnings of $2.87 per share, edging past Zacks Consensus Estimate by 22 cents. The earnings are +14.3% higher compared to the same quarter a year ago.
Net sales of the Analytical laboratory instrument manufacturing company came in at $715.02 million, beating Zacks Consensus Estimate of $702.52 million.Net sales increased +4.1% year-over-year.
Major contributors to sales growth included the company’s TA product line, strong demand in Asia (especially in China), and solid performance in the pharmaceutical market.
For 2019, Waters expects its non-GAAP earnings to be in the range of $9.20-$9.45 per share.
Medical equipment manufacturer Perkinelmer (NYSE: PKI) has pulled back in the past few months, following the rest of the market.However, there could be good news for investors of Perkinelmer as the stock hit two key support levels in the last week.
We see on the daily chart that the stock dropped down to its 104-week moving average at its low last week, but then bounced sharply from there.
Many growth stocks have gotten hurt as the market turned south again the past week.But Medpace Holdings (MEDP) is showing unusual strength, which puts it among top stocks to watch.
READ MORE: